Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:38:23.818Z.
Consensus retrieved: 2026-10-06T17:08:07.884Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:38:23.818Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8cbf2c4bedb1eff0bddc45c0acac52f2eee77af7ab0e1536e55dbd1c791948ce
Forward PE Ratio (N/A) = Dated Quote Price ($74.11) / Consensus Forward EPS ($-2.08)
FORWARD PE RATIO
N/A
Tarsus Pharmaceuticals, Inc.
Market Cap
$3.19B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | $3.19B | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A |
| CareDx, Inc (CDNA)vs › | $3.30B | 53.26 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.03B | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 32.05 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 48.12 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $74.11, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.08 | $-5.69 – $-0.80 | 4 | n/m |
| 2027-12-31 | $1.42 | $-4.17 – $4.83 | 3 | 52.2x |
| 2028-12-31 | $3.98 | $2.82 – $5.14 | 2 | 18.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
